Stocks In Focus: New York Mortgage Trust, Forestar Group Inc, Omnicare, Teva Pharmaceutical Industries Ltd

Dallas, TX -- (SBWIRE) -- 03/07/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

New York Mortgage Trust, Inc. (NASDAQ:NYMT) moved down 2.10% to $7.0 on a traded volume of 1.37 million shares. The Company reported fourth quarter consolidated net income attributable to common stockholders of $9.4 million or $0.19 per common share compared to consolidated net loss attributable to common stockholders of $1.9 million or $0.16 per common share in the same period in 2011. Book value per common share as of December 31, 2012 was $6.50, representing an increase of $0.38 per common share from the Company's book value at December 31, 2011.

Get Latest News, Updates on NYMT Here

Forestar Group Inc. (NYSE:FOR) decreased 1.92% to $20.43 on a traded volume of 1.06 million shares. So far this year, the stock is up over 18%. The 52-week range for the stock is $11.13 and $21.29. Forestar Group Inc. is a real estate and natural resources company. It owns directly or through ventures almost 147,000 acres of real estate located in nine states and 12 markets and about 595,000 net acres of mineral interests.

Is FOR a Strong Buying Opportunity After The Recent Slump? Find out Here

Omnicare, Inc. (NYSE:OCR) declined 1.79% to $37.77 on a traded volume of 1.20 million shares. The 52-week range for the stock is $29.24 and $40. The Company has Price/Sales ratio of 0.64 and Price/Book ratio of 1.13. The 50-Day Moving Average and 200-Day Moving Average prices is $38.66 and $35.66 respectively. Omnicare, Inc. is a healthcare services company. The Company operates in two primary businesses: Long-Term Care Group and Specialty Care Group.

Is OCR Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock gained 3.93% to $39.63. The company announced the publication of results of the Phase III clinical trial of Milprosa™ (progesterone) vaginal ring in Fertility and Sterility. The study compared the efficacy and safety of once-weekly Milprosa™ to daily 8 percent progesterone vaginal gel for luteal phase support in in vitro fertilization (IVF) and found that clinical pregnancy rates per retrieval at eight and 12 weeks were comparable between patient groups.

Get latest News, Updates on TEVA Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.